The Cost-Effectiveness of Octreotide Acetate in the Treatment of Carcinoid Syndrome and Vipoma
- 1 January 1998
- journal article
- general essays
- Published by Cambridge University Press (CUP) in International Journal of Technology Assessment in Health Care
- Vol. 14 (3) , 514-525
- https://doi.org/10.1017/s0266462300011491
Abstract
Markov modeling was used to evaluate the cost-effectiveness of octreotide in treating carcinoid syndrome and VIPoma. For each condition, using octreotide was associated with doubled survival time. Octreotide was cost-effective for treating carcinoid tumor ($752 per additional year of life, two additional years on average), and cost saving for VIPoma.Keywords
This publication has 1 reference indexed in Scilit:
- OctreotideNew England Journal of Medicine, 1996